[go: up one dir, main page]

PL2150617T3 - Wzmocniona ekspresja i regiony stabilności - Google Patents

Wzmocniona ekspresja i regiony stabilności

Info

Publication number
PL2150617T3
PL2150617T3 PL08756678T PL08756678T PL2150617T3 PL 2150617 T3 PL2150617 T3 PL 2150617T3 PL 08756678 T PL08756678 T PL 08756678T PL 08756678 T PL08756678 T PL 08756678T PL 2150617 T3 PL2150617 T3 PL 2150617T3
Authority
PL
Poland
Prior art keywords
enhanced expression
stability regions
regions
stability
enhanced
Prior art date
Application number
PL08756678T
Other languages
English (en)
Inventor
Gang Chen
Robert Babb
James P Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39736874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2150617(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2150617T3 publication Critical patent/PL2150617T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08756678T 2007-06-04 2008-06-04 Wzmocniona ekspresja i regiony stabilności PL2150617T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93321307P 2007-06-04 2007-06-04
PCT/US2008/065733 WO2008151219A1 (en) 2007-06-04 2008-06-04 Enhanced expression and stability regions
EP08756678.2A EP2150617B1 (en) 2007-06-04 2008-06-04 Enhanced expression and stability regions

Publications (1)

Publication Number Publication Date
PL2150617T3 true PL2150617T3 (pl) 2015-04-30

Family

ID=39736874

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08756678T PL2150617T3 (pl) 2007-06-04 2008-06-04 Wzmocniona ekspresja i regiony stabilności

Country Status (6)

Country Link
US (6) US7771997B2 (pl)
EP (1) EP2150617B1 (pl)
DK (1) DK2150617T3 (pl)
ES (1) ES2522615T3 (pl)
PL (1) PL2150617T3 (pl)
WO (1) WO2008151219A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
CN102459603B (zh) 2009-06-02 2013-11-06 瑞泽恩制药公司 岩藻糖基化缺陷型细胞
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
CN110257412B (zh) 2012-11-30 2023-12-15 落叶松生物科学公司 一种新颖的细胞系筛选方法
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
HK1220466A1 (zh) 2013-03-14 2017-05-05 Regeneron Pharmaceuticals, Inc. 爱帕琳融合蛋白和其用途
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
MX376623B (es) 2013-10-11 2025-03-07 Regeneron Pharma Cultivo celular metabolicamente optimizado.
CN103642560A (zh) * 2013-10-14 2014-03-19 无锡通用钢绳有限公司 一种钢丝绳表面脂及其制备方法
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
AU2015335921B2 (en) * 2014-10-23 2020-06-25 Regeneron Pharmaceuticals, Inc. Novel CHO integration sites and uses thereof
TW201702380A (zh) * 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
TWI804917B (zh) 2015-03-27 2023-06-11 美商再生元醫藥公司 偵測生物污染物之組成物及方法
ES2881359T3 (es) 2015-05-12 2021-11-29 Regeneron Pharma Determinación de la pureza de proteínas multiméricas
CA2987641A1 (en) 2015-07-06 2017-01-12 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
SG10202010155YA (en) * 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
TW201803981A (zh) * 2016-04-20 2018-02-01 再生元醫藥公司 用於以使用增強表現基因座爲基礎製造抗體之組成物及方法
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
US20200317738A1 (en) 2016-05-26 2020-10-08 University College Cork - National University Of Ireland, Cork Methods for increasing proliferation of mammalian cells
US11428695B2 (en) 2016-08-18 2022-08-30 Regeneron Pharmaceuticals, Inc. Concentration-dependent self-interaction assay
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
MY197672A (en) 2016-10-07 2023-07-03 Regeneron Pharma Room temperature stable lyophilized protein
EP3583205A1 (en) 2017-02-17 2019-12-25 Lonza Ltd Mammalian cells for producing adeno-associated viruses
CA3053712A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Multi-site specific integration cells for difficult to express proteins
BR112019025888A2 (pt) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica
EP3967765A1 (en) 2017-07-06 2022-03-16 FrieslandCampina Nederland B.V. Cell culture process for making a glycoprotein
CA3073615A1 (en) 2017-08-25 2019-02-28 University College Cork - National University Of Ireland Cork Bifidobacterium longum for treating obesity and weight management
US20200299729A1 (en) 2017-09-08 2020-09-24 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
US20190119701A1 (en) 2017-09-08 2019-04-25 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
CA3083711A1 (en) 2017-11-24 2019-05-31 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
EP3788075A1 (en) 2018-04-30 2021-03-10 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
MY206284A (en) 2018-05-17 2024-12-06 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
EP3604507A1 (en) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork An omega-transaminase enzyme
TWI851703B (zh) * 2019-04-02 2024-08-11 日商中外製藥股份有限公司 標的特異性外源基因的導入方法
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
CN114650834A (zh) 2019-08-20 2022-06-21 努里塔斯有限公司 用于治疗肌肉萎缩的肽
WO2021078912A1 (en) 2019-10-22 2021-04-29 Nuritas Limited Treatment of non-alcoholic fatty liver disease
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
EP4070670A1 (en) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 and uses thereof
EP4322983A1 (en) 2021-04-14 2024-02-21 University College Cork-National University of Ireland Cork Treatment of cerebrovascular events and neurological disorders
WO2022219168A1 (en) 2021-04-14 2022-10-20 University College Cork - National University Of Ireland, Cork Psg1 for use in the treatment of osteoarthritis
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
AU2022373653A1 (en) 2021-10-18 2024-05-02 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
EP4419698A1 (en) 2021-10-18 2024-08-28 Regeneron Pharmaceuticals, Inc. Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
TW202330926A (zh) 2021-10-18 2023-08-01 美商再生元醫藥公司 聚核苷酸之受控制轉錄
JP2025534040A (ja) 2022-10-14 2025-10-09 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 腱傷害の治療における使用のための胎盤発現タンパク質
WO2025133254A2 (en) 2023-12-20 2025-06-26 Nuritas Limited Angiotensin-converting enzyme (ace) inhibiting peptides.
WO2025133189A1 (en) 2023-12-20 2025-06-26 Nuritas Limited Sleep promoting peptides and the use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US6689606B2 (en) * 1998-07-21 2004-02-10 M.L. Laboratories Plc Polynucleotide
WO2002081632A2 (en) * 2001-04-04 2002-10-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acids for transgene expression
FR2910490B1 (fr) 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions

Also Published As

Publication number Publication date
US7771997B2 (en) 2010-08-10
US8389239B2 (en) 2013-03-05
US20100291626A1 (en) 2010-11-18
WO2008151219A1 (en) 2008-12-11
US9932605B2 (en) 2018-04-03
US9562238B2 (en) 2017-02-07
EP2150617A1 (en) 2010-02-10
US20170096681A1 (en) 2017-04-06
US20130130372A1 (en) 2013-05-23
EP2150617B1 (en) 2014-10-22
US10415055B2 (en) 2019-09-17
DK2150617T3 (en) 2015-01-12
ES2522615T3 (es) 2014-11-17
US9222106B2 (en) 2015-12-29
US20090124005A1 (en) 2009-05-14
US20160097059A1 (en) 2016-04-07
US20180327777A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
PL2150617T3 (pl) Wzmocniona ekspresja i regiony stabilności
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
EP2185692A4 (en) HCO32 AND HCO27 AND RELATED EXAMPLES
IL210804A (en) Benzylidenehydrazides and their uses
EP2069496A4 (en) SELEX AND PHOTOSELEX ENHANCED
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA200810323B (en) Fkbp-l and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
PT2114900T (pt) Compostos à base de tiopirimidina e as suas utilizações
HUE059436T2 (hu) PSMA-kötõ szerek és alkalmazásaik
IL211742A0 (en) Frizzled-binding agents and uses thereof
PL2064327T3 (pl) Dbait i ich zastosowania
GB0808575D0 (en) Compilign and linking
GB0921531D0 (en) Playpen and related playpen set
GB0822154D0 (en) Recepatacle and support
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
ZA200903906B (en) Carboranylporphyrins and uses thereof
ZA201103456B (en) Leukolectins and uses thereof
IL208771A0 (en) Iminopyridine derivatives and use thereof
EP2247601A4 (en) THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
ZA201001402B (en) Mouse and stay thereof
EP2274294A4 (en) 5-DIMETHOXY FUMAGILLOL AND ITS DERIVATIVES
IL206951A0 (en) 3-alkyl-piperazine derivatives and uses thereof
GB0813359D0 (en) Halfin and/or platerfin